FDA wants preclinical data on XenoPort's Horizant

Shares of XenoPort were buoyed by the news that regulators had asked for preclinical data on its experimental therapy for restless leg syndrome but were not asking for any new trials. XenoPort plans to file a complete response to the FDA in the second half of the year. "We believe this is an incremental positive for the company as a path toward an approval of Horizant has been identified," said Leerink Swann analyst Steve Yoo. Report

Suggested Articles

In the first half of 2020, the regenerative medicine sector raised $10.7 billion, more than the total it raised in 2019.

The trial linked RG6346 to reductions in hepatitis B surface antigen that suggest the RNAi therapy can hold its own against drugs from J&J and Vir.

Creating new, successful central nervous system drugs is tough, and Lundbeck knows this better than most after canning an internal CNS effort.